Zobrazeno 1 - 10
of 222
pro vyhledávání: '"Frank, E. Jones"'
Autor:
Richard Schroeder, Mary Sfondouris, Navneet Goyal, Rajesh Komati, Achira Weerathunga, Cory Gettridge, Cheryl L. Klein Stevens, Frank E. Jones, Jayalakshmi Sridhar
Publikováno v:
ACS Omega, Vol 4, Iss 6, Pp 10610-10619 (2019)
Externí odkaz:
https://doaj.org/article/091c4fb29bec45f49658eae7c21e498e
Autor:
Heng Zhang, Ling Zhang, Dongming Zhou, Xiao He, Dongpi Wang, Hongyu Pan, Xiaoqin Zhang, Yufei Mei, Qi Qian, Tingting Zheng, Frank E. Jones, Binggui Sun
Publikováno v:
Neurobiology of Disease, Vol 106, Iss , Pp 171-180 (2017)
Accumulation of amyloid β (Aβ) induces neuronal, synaptic, and cognitive deficits in patients and animal models of Alzheimer's disease (AD). The underlying mechanisms, however, remain to be fully elucidated. In the present study, we found that Aβ
Externí odkaz:
https://doaj.org/article/ba2813ffe31f47f08148beb0e2eb4d45
Autor:
Frank E. Jones, Edi Brogi, Samuel M. Lesko, Jenny G. Parvani, Tamika T. Duplessis, Yun Zhu, Stella U. Okamgba, Michael J. Brumlik, Doyel Mitra
Supplementary Table 1. Clinical characteristics of 85 primary breast tumors used for statistical analysis; Supplementary Table 2. HER2 and HER2�16 coexpression compared clinicopathological parameters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b968296ce569d6cb04cb32432d8bbf
https://doi.org/10.1158/1535-7163.22485182
https://doi.org/10.1158/1535-7163.22485182
Autor:
Frank E. Jones, Edi Brogi, Samuel M. Lesko, Jenny G. Parvani, Tamika T. Duplessis, Yun Zhu, Stella U. Okamgba, Michael J. Brumlik, Doyel Mitra
The HER2-targeted therapy trastuzumab is widely used for the treatment of patients with metastatic breast tumors overexpressing HER2. However, an objective response is observed in only 12% to 24% of patients treated with trastuzumab as a single agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f8a27878f5ab9d8f8d30ebcfff12d2c
https://doi.org/10.1158/1535-7163.c.6531818.v1
https://doi.org/10.1158/1535-7163.c.6531818.v1
Autor:
Frank E. Jones, Edi Brogi, Samuel M. Lesko, Jenny G. Parvani, Tamika T. Duplessis, Yun Zhu, Stella U. Okamgba, Michael J. Brumlik, Doyel Mitra
Supplementary Data from An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8156baa739bd70e58c55080a0beb227a
https://doi.org/10.1158/1535-7163.22485185
https://doi.org/10.1158/1535-7163.22485185
Autor:
Frank E. Jones, John M.S. Bartlett, Timothy G. Cooke, Sian Tovey, Carolyn I. Sartor, Luis Marrero, William C. Wimley, Gregory A. Vidal, Weiwen Long, Anjali Naresh
ERBB4/HER4 (referred to here as ERBB4) is a unique member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. In contrast to the other three members of the EGFR family (i.e., EGFR, ERBB2/HER2/NEU, and ERBB3), which are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7104a3b3177de3b0bc854bb19d154d41
https://doi.org/10.1158/0008-5472.c.6494600
https://doi.org/10.1158/0008-5472.c.6494600
Autor:
Frank E. Jones, John M.S. Bartlett, Timothy G. Cooke, Sian Tovey, Carolyn I. Sartor, Luis Marrero, William C. Wimley, Gregory A. Vidal, Weiwen Long, Anjali Naresh
Supplementary Figure 1 from The ERBB4/HER4 Intracellular Domain 4ICD Is a BH3-Only Protein Promoting Apoptosis of Breast Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072169dad2481e5a459b40954bd7fc17
https://doi.org/10.1158/0008-5472.22365239
https://doi.org/10.1158/0008-5472.22365239
Autor:
Frank E. Jones, Rakesh Kumar, Kathleen C. Torkko, Susan M. Edgerton, Ann D. Thor, Anjali Naresh
Greater than 40% of breast cancer patients treated with tamoxifen exhibit de novo or acquired tumor resistance. Recent clinical evidence indicates that loss of expression of HER4 is an independent marker for tamoxifen resistance. In direct corroborat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a148ef3a84d2b6725add6987a05c4d9
https://doi.org/10.1158/0008-5472.c.6497466
https://doi.org/10.1158/0008-5472.c.6497466
Autor:
Frank E. Jones, Rakesh Kumar, Kathleen C. Torkko, Susan M. Edgerton, Ann D. Thor, Anjali Naresh
Supplementary Figure 1 from The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b9ad272e11aae61c55e121b7739398a
https://doi.org/10.1158/0008-5472.22374486.v1
https://doi.org/10.1158/0008-5472.22374486.v1
Autor:
Felicia C Huynh, Frank E Jones
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114419 (2014)
The oncogenic isoform of HER2, HER2Δ16, is expressed with HER2 in nearly 50% of HER2 positive breast tumors where HER2Δ16 drives metastasis and resistance to multiple therapeutic interventions including tamoxifen and trastuzumab. In recent years mi
Externí odkaz:
https://doaj.org/article/ab7b82ca9e98442ca719effa8e8726b9